Introduction
Eosinophilic esophagitis (EoE) is a chronic, allergy-driven inflammatory disease of the esophagus characterized by dense eosinophil infiltration resulting from T cell–mediated responses to dietary or airborne allergens. Patients frequently experience dysphagia and food impactions, greatly affecting quality of life. Treatment response is currently assessed through invasive mucosal biopsies, requiring eosinophil counts to fall below 15 cells per high-power field. Because this approach is burdensome, there is a need for noninvasive markers of disease activity. This study examined changes in eosinophil-associated markers before and after proton pump inhibitor therapy and compared these profiles with healthy individuals to identify potential blood-based biomarkers.
Aims & Methods
Seventeen adults with EoE provided blood samples, esophageal biopsies, and symptom assessments using the Watson Dysphagia Scale (WDS) and Eosinophilic Esophagitis Activity Index (EEsaI) before and after 12 weeks of proton pump inhibitor treatment (omeprazole 20 mg twice daily). Biopsies were evaluated for eosinophils per high-power field and with the Eosinophilic Esophagitis Histologic Scoring System (EoE-HSS). Blood samples from 17 healthy controls were included. Endoscopic findings were scored using the Eosinophilic Esophagitis Endoscopic Reference Score (EREFS). To characterize eosinophil subpopulations, we designed an antibody panel for eosinophil markers and analyzed samples by mass cytometry (CyTOF), using FlowSOM and Opt-SNE for clustering and visualization.
Results
Twelve patients (71%) responded to proton pump inhibitor treatment and achieved fewer than 15 peak eosinophils per high-power field, while five did not respond. In the responder group, eosinophils per high-power field decreased from a mean of 45 (range 16–108) before treatment to 2 (range 0–9) after treatment. Scores from the Eosinophilic Esophagitis Histologic Scoring System also improved, with grade scores falling from 0.6 to 0.2 and stage scores from 0.8 to 0.4. FlowSOM analysis identified ten distinct eosinophil clusters, of which two decreased significantly following treatment; these were characterized by galectin-10–positive and CD16-positive eosinophils. Opt-SNE visualization further showed that FOXP3-expressing populations expanded after treatment, a pattern not observed in nonresponders. Clinically, most patients reported reduced symptom burden after treatment, as reflected by improvements in Watson Dysphagia Scale scores (mean 18 to 14) and Eosinophilic Esophagitis Activity Index scores (mean 45 to 31). Endoscopic findings also improved, with Eosinophilic Esophagitis Endoscopic Reference Score values decreasing from a mean of 3.0 to 1.9.
Conclusion
Blood-based eosinophil markers show promise as noninvasive indicators of treatment response in eosinophilic esophagitis and may help clarify the role of esophageal eosinophils.
Disclosure
All authors declare no conflict of interest.